CoChat

Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic

Jardim, Denis L.F., Tang, Chad, Gagliato, Debora De Melo, Falchook, Gerald S., Hess, Kenneth, Janku, Filip, Fu, Siqing, Wheler, Jennifer J., Zinner, Ralph G., Naing, Aung, Tsimberidou, Apostolia M., Holla, Vijaykumar, Li, Marylin M., Roy-Chowdhuri, Sinchita, Luthra, Raja, Salgia, Ravi, Kurzrock, Razelle, Meric-Bernstam, Funda, Hong, David S. · 2014 · Clinical Cancer Research
Cited by 81

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Purpose: This study aimed to assess MET amplification among different cancers, association with clinical factors and genetic aberrations and targeted therapy response modifications. Experimental Design: From May 2010 to November 2012, samples from patients with advanced tumors referred to the MD Anderson Phase I Clinic were analyzed for MET gene amplification by FISH. Patient demographic, histologic characteristics, molecular characteristics, and outcomes in phase I protocols were compared per MET amplification status. Results: Of 1,115 patients, 29 (2.6%) had MET amplification. The highest prevalence was in adrenal (2 of 13; 15%) and renal (4 of 28; 14%) tumors, followed by gastroesophageal (6%), breast (5%), and ovarian cancers (4%). MET amplification was associated with adenocarcinomas (P = 0.007), high-grade tumors (P = 0.003), more sites of metastasis, higher BRAF mutation, and PTEN loss (all P < 0.05). Median overall survival was 7.23 and 8.62 months for patients with and without a MET amplification, respectively (HR = 1.12; 95% confidence intervals, 0.83–1.85; P = 0.29). Among the 20 patients with MET amplification treated on a phase I protocol, 4 (20%) achieved a partial response with greatest response rate on agents targeting angiogenesis (3 of 6, 50%). No patient treated with a c-MET inhibitor (0 of 7) achieved an objective response. Conclusion: MET amplification was detected in 2.6% of patients with solid tumors and was associated with adenocarcinomas, high-grade histology, and higher metastatic burden. Concomitant alterations in additional pathways (BRAF mutation and PTEN loss) and variable responses on targeted therapies, including c-MET inhibitors, suggest that further studies are needed to target this population. Clin Cancer Res; 20(24); 6336–45. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-1293

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 81

Metadata

Authors
Jardim, D. L. F., Tang, C., Gagliato, D. D. M., Falchook, G. S., Hess, K., Janku, F., Fu, S., Wheler, J. J., Zinner, R. G., Naing, A., Tsimberidou, A. M., Holla, V., Li, M. M., Roy-Chowdhuri, S., Luthra, R., Salgia, R., Kurzrock, R., Meric-Bernstam, F., & Hong, D. S.
Venue
Clinical Cancer Research
Published
2014-12-14
Volume
20
Issue
24
Pages
6336-6345
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2062069596
Cited by
81
References
3
FWCI
8.48
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-1293
The paper
Jardim, D. L. F., Tang, C., Gagliato, D. D. M., Falchook, G. S., Hess, K., Janku, F., Fu, S., Wheler, J. J., Zinner, R. G., Naing, A., Tsimberidou, A. M., Holla, V., Li, M. M., Roy-Chowdhuri, S., Luthra, R., Salgia, R., Kurzrock, R., Meric-Bernstam, F., & Hong, D. S. (2014). Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-1293

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.